Anticoagulation in percutaneous coronary intervention
Interventional Cardiology · 2010-08 · 2 (4) · 559-577
DOI: 10.2217/ica.10.46 ↗Kurz gefasst
Fachartikel in der Zeitschrift Interventional Cardiology, 2010-08. Verfasst von Brian P O’Neill und 2 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben.
Abstract (Originalsprache)
Balancing safety and efficacy of anticoagulation strategies is a fundamental goal in the performance of percutaneous coronary interventions. The ideal anticoagulant in the catheterization laboratory should effectively prevent thrombosis, yield a low bleeding risk, be titratable to individual clinical needs, be reversible when clinically indicated and be administered without the need for complicated infusions or routine monitoring. Despite its many drawbacks, unfractionated heparin continues to be the most commonly used anticoagulant in percutaneous coronary intervention. Nevertheless, anticoagulation options in the catheterization laboratory have grown substantially over the past 20 years and now include direct thrombin inhibitors, low-molecular-weight heparin molecules and Factor X inhibitors. Additional options are anticipated in the near future with novel agents targeting upstream factors in the coagulation cascade. The availability of multiple anticoagulation options allows for a tailored approach bas...
Zitieren
APA
O’Neill, B. P., Shaw, E. S., & Cohen, M. G. (2010). Anticoagulation in percutaneous coronary intervention. Interventional Cardiology, 2(4), 559-577. https://doi.org/10.2217/ica.10.46
Vancouver
O’Neill BP, Shaw ES, Cohen MG. Anticoagulation in percutaneous coronary intervention. Interventional Cardiology. 2010;2(4):559-577. doi:10.2217/ica.10.46
BibTeX
@article{ONeill2010,
author = {O’Neill, Brian P and Shaw, Eric Scot and Cohen, Mauricio G},
title = {Anticoagulation in percutaneous coronary intervention},
journal = {Interventional Cardiology},
year = {2010},
volume = {2},
number = {4},
pages = {559--577},
doi = {10.2217/ica.10.46}
}
EUVIMED